BioSpecifics Technologies Corp (BSTC)
(Delayed Data from NSDQ)
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$66.72 USD
+0.21 (0.32%)
Updated May 3, 2019 04:00 PM ET
After-Market: $66.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Lannett (LCI) Could Be Positioned for a Slump
by Zacks Equity Research
Lannett (LCI) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap
by Zacks Equity Research
Aldeyra Therapeutics' (ALDX) dry eye candidate, reproxalap, achieves early onset of improvement in patients and a broad range of activity.
Adamis Pharmaceuticals (ADMP) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.
Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status
by Zacks Equity Research
Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
by Zacks Equity Research
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda
by Zacks Equity Research
Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.
Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies
by Zacks Equity Research
Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
Rigel Pharmaceuticals (RIGL) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Ironwood Stock Up, Heart Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA confers fast track designation on Ironwood's (IRWD) praliciguat for the treatment of heart failure with preserved ejection fraction.
KemPharm Posts Positive Top-Line Results on KP415 Prodrug
by Zacks Equity Research
KemPharm (KMPH) reports positive top-line results from second of three HAP studies on serdexmethylphenidate/KP415 Prodrug, which is contained in lead candidate KP415 that is being developed for ADHD.
Tilray (TLRY) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
Tilray (TLRY) was a big mover last session, as the company saw its shares rise more than 8% on the day amid huge volumes.
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
5 Top-Ranked Nasdaq Stocks Defying the Worst September Start
by Sweta Killa
There are still winners on the index across industries that are easily surviving the worst start to September and have a solid Zacks Rank #1 (Strong Buy) or 2 (Buy).
Spectrum Pharmaceuticals (SPPI) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) shares rose nearly 6% in the last trading session, amid huge volumes.
Tesaro (TSRO) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Tesaro (TSRO) shares rose nearly 6% in the last trading session, amid huge volumes.
What Makes Taro Pharmaceutical (TARO) a Strong Sell?
by Zacks Equity Research
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Zacks.com highlights: Verso, Johnson Outdoors, BioSpecifics Technologies and Luxfer Holdings
by Zacks Equity Research
Zacks.com highlights: Verso, Johnson Outdoors, BioSpecifics Technologies and Luxfer Holdings
BioCryst Pharmaceuticals (BCRX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
4 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Affimed (AFMD) Soars: Stock Adds 10.8% in Session
by Zacks Equity Research
Affimed (AFMD) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.
Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol
by Zacks Equity Research
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1%
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) shares rose more than 9% in the last trading session, amid huge volumes.